Table 3.
Change from baseline (mean ± SD) in immunoglobulin concentrations and lymphocyte densities at 6 h following single mizoribine doses (N = 32, six per dose level)
| Pharmacodynamic parameters | 3 mg kg−1 | 6 mg kg−1 | 9 mg kg−1 | 12 mg kg−1 | Placebo |
|---|---|---|---|---|---|
| IgG (mg dl−1) | −154.3 ± 70.0 | 74.3 ± 150.9 | −18.0 ± 57.7 | 0.2 ± 40.9 | −102.4 ± 147.3 |
| IgM (mg dl−1) | −10.2 ± 34.8 | 111.5 ± 122.8 | 5.8 ± 5.1 | −2.3 ± 7.3 | −38.3 ± 58.9 |
| IgA (mg dl−1) | 35.7 ± 53.2 | 38.8 ± 77.3 | 4.3 ± 7.8 | 0.0 ± 9.4 | −53.6 ± 74.9 |
| CD4+ (cells µl−1) | −148.2 ± 240.0 | −34.2 ± 117.2 | −84.2 ± 249.1 | −35.3 ± 289.7 | −44.4 ± 220.4 |
| CD8+ (cells µl−1) | −119.5 ± 95.2 | −65.7 ± 39.2 | −201.5 ± 320.8 | −16.0 ± 83.2 | −61.4 ± 96.0 |